JAK Inhibitors Video Perspectives

In this video series, Namrata Singh, MD, MSCI, FACP, rheumatologist at University of Washington School of Medicine, spoke about:

• how the field of JAK inhibitors is “continuing to evolve;”
• PAISLEY trial results and other interesting data on JAKs presented at ACR 2022;
• using JAK inhibitors in combination with conventional synthetic DMARDs;
• positioning first- and second-generation JAK inhibitors and selecting treatment based on individual patient comorbidities;
• how the elevated risk for cardiovascular events linked to a specific JAK inhibitor has had “a huge impact” on patients and providers; and
• the importance of shared decision-making in selecting a JAK inhibitor treatment.